Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma
- 1 January 2019
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 42 (1) , 42-45
Abstract
Objective: The activity of cabozantinib in nonclear cell histologies has not been evaluated. Materials and Methods: Data were collected across 24 Italian hospitals. Patients were aged 18 years and older with advanced nonclear cell renal cell carcinoma (RCC), with an Eastern Cooperative Oncology Group Performance Status 0 to 2, who had relapsed after previous systemic treatments for metastatic disease. Cabozantinib was administered orally at 60 mg once a day in 28 days cycles. Dose reductions to 40 or 20 mg were made due to toxicity. Adverse events (AEs) were monitored using CTCAE version 4.0. Results: Seventeen patients were enrolled. Three (18%) patients were diagnosed type I papillary RCC, 9 (53%) type II papillary, 3 (18%) chromophobe, and 2 (11%) with Bellini duct carcinoma. In total, 11 patients started with 60 mg. Six patients started a lower dose of 40 mg. Median progression-free survival was 7.83 months (0.4 to 13.4 mo), while median overall survival was not reached but 1-year overall survival was about 60%. Six patients (35%) experienced a partial response to treatment and 6 patients (35%) showed a stable disease. In the remaining 5 (30%), we observed a progressive disease. Grade 3 and 4 AEs were observed in 41% of patients. Among 20 patients, only 1 (6%) discontinued treatment due to AEs. Asthenia (41%), diarrhea (35%), aminotransferase increasing (35%), mucosal inflammation (35%), hand and foot syndrome (24%), and hypothyroidism (24%) were the most frequently AEs. Conclusions: Our data showed that, cabozantinib is a active and feasible treatment in patient with nonclear cell RCC.Keywords
This publication has 23 references indexed in Scilit:
- Personalized therapy in renal cell carcinoma: are the different tyrosine kinase inhibitors the same for any patient?Expert Review of Precision Medicine and Drug Development, 2017
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular TumoursEuropean Urology, 2016
- Renal cancerThe Lancet, 2016
- Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and METProceedings of the National Academy of Sciences, 2014
- Targeting the Hepatocyte Growth Factor/c-Met Signaling Pathway in Renal Cell CarcinomaThe Cancer Journal, 2013
- Management of Renal Collecting Duct Carcinoma: A Systematic Review and the McMaster ExperienceCurrent Oncology, 2013
- Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteriaCancer, 2013
- c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinomaAnnals of Oncology, 2012
- Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screenProceedings of the National Academy of Sciences, 2008
- The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma CellsMolecular and Cellular Biology, 1999